Evidence map›Paper›PMID 42717134›Full record

ArticleJournal of neuro-oncology2026

Diffusion histogram analysis predicts progression-free survival in contrast enhancing recurrent IDH mutant gliomas treated with bevacizumab.

Elizabeth Loxterkamp, Audrey Luo, Francesco Sanvito, Collin T Le, Catalina Raymond, Chuyin Yang, Terry J Prins, Addison Fisher, Noriko Salamon, Linda M Liau and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Elizabeth LoxterkampUCLA Brain Tumor Imaging Laboratory (BTIL), Department of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, 924 Westwood Blvd, Suite 615, Los Angeles, CA, 90024, USA.
Audrey LuoUCLA Brain Tumor Imaging Laboratory (BTIL), Department of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, 924 Westwood Blvd, Suite 615, Los Angeles, CA, 90024, USA.
Francesco SanvitoUCLA Brain Tumor Imaging Laboratory (BTIL), Department of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, 924 Westwood Blvd, Suite 615, Los Angeles, CA, 90024, USA.
Collin T LeDepartment of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Catalina RaymondUCLA Brain Tumor Imaging Laboratory (BTIL), Department of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, 924 Westwood Blvd, Suite 615, Los Angeles, CA, 90024, USA.
Chuyin YangDepartment of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Terry J PrinsDepartment of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Addison FisherDepartment of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Noriko SalamonUCLA Brain Tumor Imaging Laboratory (BTIL), Department of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, 924 Westwood Blvd, Suite 615, Los Angeles, CA, 90024, USA.
Linda M LiauDepartment of Neurosurgery, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Robert A ChongDepartment of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Phioanh L NghiemphuDepartment of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
David A NathansonDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Timothy F CloughesyDepartment of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Albert LaiDepartment of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Benjamin M EllingsonUCLA Brain Tumor Imaging Laboratory (BTIL), Department of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, 924 Westwood Blvd, Suite 615, Los Angeles, CA, 90024, USA. bellingson@mednet.ucla.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPretreatment apparent diffusion coefficient (ADC) histogram analysis-specifically the lower Gaussian peak mean (ADC-L)-is a predictive biomarker of progression-free survival (PFS) and overall survival (OS) in recurrent IDH-wildtype glioblastoma receiving anti-VEGF treatment including bevacizumab. IDH-mutant gliomas differ biologically from glioblastoma, as they exhibit lower tumor cellularity, longer survival, and distinct sensitivity to a variety of therapies. Whether ADC-L retains predictive utility in IDH-mutant recurrent glioma has not been established.

methodsIn this retrospective, single-center study, sixty patients with IDH-mutant recurrent glioma (41 astrocytoma, 19 oligodendroglioma) with measurable contrast enhancement and available pretreatment diffusion-weighted MRI who received bevacizumab were analyzed. Univariate and multivariate Cox regression and Kaplan-Meier analyses were performed for PFS and OS.

resultsThe optimal ADC-L threshold was 1.19 μm

conclusionsPretreatment ADC-L predicts PFS in IDH-mutant recurrent glioma receiving bevacizumab. Supporting prospective evaluation of ADC-L as a biomarker for bevacizumab patient selection in this population.

Indexed as

Antineoplastic Agents, ImmunologicalBevacizumabBrain NeoplasmsDiffusion Magnetic Resonance ImagingGliomaNeoplasm Recurrence, LocalAdultAgedFemaleFollow-Up StudiesHumansIsocitrate DehydrogenaseMaleMiddle AgedMutationPrognosisAntineoplastic Agents, ImmunologicalBevacizumabIDH1 protein, humanIsocitrate DehydrogenaseBevacizumabDiffusion histogram analysisIDH mutant

Identifiers

PMID42717134
PMCPMC13558324

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.